1. Supplementary Figure 1 a b c d e 1 2 cGMP levels (pmol/ml) vehicle1 2
cGMP levels (pmol/ml)
vehicle
Wnt3a c
10 0
10 1
10 2
10 3
0.61%
2.28%
96.33%
0.78% B1 B2 B3 B4
FL3-PI
0.53%
95.88%
1.13%
0.73%
2.02%
96.44%
0.81%
0.96%
2.43%
95.4%
1.21%
FL1-Annexin V FITC
Ctrl
Tadalafil 5 μM
Tadalafil 10 μM
Tadalafil 1 μM 4 ** L
Lef1 Luc. activity (RLU)
Wnt3a 3 † ‡ 2 1 ** 1 5 10
Vardenafil (μM) d
10 0
10 1
10 2
10 3
0.44%
2.71%
96.37%
1.02% B1 B2 B3 B4
FL3-PI
0.53%
2.28%
95.88%
1.13%
0.64%
2.16%
96.47%
0.73%
0.78%
2.81%
95.16%
1.25%
FL1-Annexin V FITC
Ctrl
KT μM
KT μM
KT μM e
10 0
10 1
10 2
10 3
0.20%
1.06%
96.74%
2.00% B1 B2 B3 B4
FL3-PI
0.27%
0.87%
95.44%
3.41%
0.31%
1.07%
93.58%
5.04%
0.14%
0.72%
96.28%
2.86%
FL1-Annexin V FITC
Ctrl
Tadalafil 5 μM
Tadalafil 10 μM
Tadalafil 1 μM
Supplementary Figure 1

2. Supplementary Figure 2 a b 0.4 0.8 1.2 1.6 b-catenin mRNA levels
0.4
0.8
1.2
1.6
b-catenin mRNA levels
Tadalafil (μM) 5 10 b
β-catenin
p45-
Wnt3a
Tada. - +
β-actin L
Supplementary Figure 2

3. Supplementary Figure 3 b a SFRP1+/- SFRP1-/-
100
200
300
400
500
600
700
TRAP staining positive cells/mm3
SFRP1+/ SFRP1-/-
Mice
Tad.
(mg/kg) 75 a
50 mm
20 mm
SFRP1+/ SFRP1-/-
Normal saline Tadalafil (75mg/kg)
Supplementary Figure 3

4. Supplementary Figure 4 a b c d 0.5 1.0 1.5 2.0 2.5 3.0 3.5 0.1 0.2 0.3
0.5
1.0
1.5
2.0
2.5
3.0
3.5
0.1
0.2
0.3
0.4
0.6
1/mm
0.7 mm
Tadalafil (mg/kg) 75 45
SFRP1-/-
TbTh
TbSp
SFRP1+/-
Tadalafil
(mg/kg)
TbN * ** ‡ a b c d
Supplementary Figure 4